论文部分内容阅读
目的本研究旨在评价肝动脉化疗栓塞术后经皮无水乙醇注射术补充治疗对原发性肝细胞癌(HCC)疾病进程和总生存期的影响。方法全部73例HCC,临床分期均为中国分期Ⅱ期,并接受至少2次肝动脉栓塞化疗。治疗组22例,于肝动脉栓塞化疗(TACE)后补充经皮无水乙醇消融术(PEI),对照组51例TACE后未予补充治疗,比较两组疾病进展时间与生存期差异,并作预后因素分析。结果治疗组与对照组中位疾病进展时间分别为10个月(95%可信区间7.9,12.1)和6个月(95%可信区间4.7,7.3)。治疗组3个月、6个月、1年无进展生存率为77.30%、63.61%、48.12%,对照组3个月、6个月、1年无疾病进展率为76.51%、42.17%、24.82%,两组有显著差别(log-rank检验,P<0.05)。两组中位生存期分别为17个月(95%可信区间11,23)、12个月(95%可信区间10,14),总生存期无显著差异(P>0.05)。结论TACE术后补充PEI能明显延长HCC无进展生存期。
Objectives This study was designed to evaluate the effect of percutaneous ethanol infusion after transcatheter hepatic artery chemoembolization on the progression and overall survival of patients with primary hepatocellular carcinoma (HCC). Methods All 73 patients with HCC were enrolled in this study. All patients underwent clinical staging of stage II in China and received at least 2 cycles of hepatic arterial chemoembolization. Twenty-two patients in the treatment group were treated with percutaneous ethanol ablation (PEI) after TACE and 51 patients in the control group were treated with TACE. The differences in the progression time and the survival time between the two groups were compared Prognostic factors. Results The median time to progression in the treatment and control groups was 10 months (95% confidence interval 7.9, 12.1) and 6 months (95% confidence interval 4.7, 7.3), respectively. The 3-month, 6-month, 1-year progression-free survival rates in the treatment group were 77.30%, 63.61%, 48.12%. The control group had no disease progression rates of 76.51%, 42.17%, and 24.82 at 3 months, 6 months and 1 year %, Significant difference between the two groups (log-rank test, P <0.05). The median survival was 17 months (95% confidence interval 11,23) and 12 months (95% confidence interval 10,14) respectively, with no significant difference in overall survival (P> 0.05). Conclusion TACE postoperative PEI can significantly prolong the progression-free survival of HCC.